Abstract: The present disclosure provides a dimer formed by two polypeptide chains, with each of the two polypeptide chains comprising an antibody Fc subunit, wherein the dimer comprises two or more immunoglobulin single variable domains (ISVDs), at least one of the ISVDs is specific for PD-L1, and at least one of the ISVDs is specific for CTLA4.

Abstract: The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise specific substitution mutations combination, for example, for the first CH3 domain: T366W+F405K, and for the second CH3 domain: T366S+L368A+Y407V+K409A.

Abstract: Nanoscopic dispersion of trace enzymes and random heteropolymers in plastics provides to fully functional plastics with eco-friendly microplastic elimination and programmable degradation.

Abstract: Compositions comprise statistically random heteropolymers complexed with active proteins, and are formulated and used in stimuli-responsive materials and nanoreactors composed of proteins and synthetic materials.

Abstract: Methods and compositions wherein crystalline woven and interlocked covalent organic frameworks (COFs) are used as additives to achieve combinations of high toughness and elasticity in polymers.

Abstract: The present invention relates to a method for preventing and/or treating thromboembolic diseases, comprising the following step: administering a coagulation factor XI (FXI) binding protein to a subject in need thereof, which binding protein can comprise at least one immunoglobulin single variable domain capable of specifically binding to FXI, wherein the at least one immunoglobulin single variable domain may comprise CDR1, CDR2, and CDR3 in a VHH as shown in any one of SEQ ID NOs: 4, 10, and 14.